Replies to post #157116 on Biotech Values

[biomaven0]

>NEO

I still own the stock in decent size, but have recently taken some off the table - my one concern is the potential for CMS reimbursement changes for molecular tests.

http://www.aacc.org/publications/cln/2011/September/Pages/MolecularDxReimbursement.aspx

Palmetto is leading the charge and using this as an opportunity to cut reimbursement, although that was not the stated purpose of these changes.

Still think that someone will acquire them.

Peter

[DewDiligence]

NEO…reported that most of the TC grandfather sunset is now behind them…

What is the TC grandfather sunset?